

Company name: QuantHealth

Website: www.QuantHealth.ai

CEO Name: Orr Inbar

CATEGORY: Health IT/Digital

SESSION: Reinventing Clinical Trials

Executive Summary / Investment Rationale

QuantHealth is the global leader in AI-powered clinical trial simulation and is trusted by 12 of the top 20 pharma. The company combines the industry's most advanced clinical trial simulations portfolio -- spanning 600+ trials and 30 indications with up to 90% accuracy -- with one of the largest real-world datasets in the category. Its solutions enable life sciences to optimize trial design, reduce risk, and accelerate development timelines. QuantHealth is backed by Accenture Ventures, Bertelsmann Investments, Nina Capital, Pitango, Sanofi Ventures, and Shoni Top Ventures.

Core Technology: What is the technology, its uniqueness, and its value proposition?

The QuantHealth Large Real-World Drug Model (LRDM) is the industry's first "pharmaco-clinical foundation model" focused on accelerating life sciences' ability to more quickly and effectively develop medicines through clinical trial simulations. QuantHealth's LRDM harnesses data from 100M patients, 30B drug-patient pairs, and 100,000+ therapeutics for simulations done in a fraction of the time, while still delivering up to 90% accuracy in predicting trial results.

Product Profile/Pipeline: Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

Clinical trials remain one of the most costly and uncertain phases of drug development, with more than [90% of drugs failing, costing the industry more than \\$50 billion annually](#).

QuantHealth's LRDM is currently used to support clinical strategy across 30+ indications, with plans to expand into new indications in high-growth therapeutic areas, including oncology, cardiometabolic, inflammation & immunology. The company will also soon launch commercial capabilities, such as competitor positioning and go-to-market decision support, enabling organizations to better assess market potential and optimize commercialization strategies before committing significant capital.

Business Strategy: Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

Following 8x revenue growth in 2025, the company is focused on expanding contracts with existing life sciences clients, while growing its footprint among additional pharmaceutical and biotech leaders.

What's Next? R&D, Preclinical / Clinicals, Organizational

The company will continue to prioritize R&D by building end-to-end clinical trial simulation capabilities. This includes supporting protocol optimization, indication and asset prioritization, patient stratification, enrollment forecasting, commercial positioning, and portfolio-level decision-making.

Additionally, the company plans to expand its clinical trial simulation capabilities into new indications and enhance performance to achieve 90% accuracy across its indications within the next 18–24 months.